ALSYMPCA Trial Articles

Articles

24th Int'l Prostate Cancer Update: Poster - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

VAIL, CO USA (UroToday.com) - Presented by Peter Hoskin, Mona Wahba, John Logue, David Bottomley, Sten Nilsson, Fang Fang, Jose Garcia-Vargas, Karin Staudacher, Paul Cislo, Jonathan Reuning-Scherer, and Christopher Parker at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

Published February 21, 2014
A Review on the Development of Targeted Alpha Therapy in the Treatment of Cancer

Published in Everyday Urology - Oncology Insights: Volume 2, Issue 2
Published Date: June 2017

Focusing on The First and Only FDA Approved Targeted Alpha Therapy Radium-223 in the Treatment of mCRPC

The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University
Published September 5, 2017
ASCO 2013 - Poster: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes

CHICAGO, IL USA (UroToday.com) - Presented by O. Sartor,¹ R. Amariglio,² S. Wilhelm,² J. Garcia-Vargas,² C.G. O’Bryan-Tear,³ M. Shan,² F. Fang,² and C. Parker⁴ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Published June 10, 2013
CUA 2017: Analysis of Real-World use of Radium-223 in Ontario
Toronto, Ontario (UroToday.com) Dr. Urban Emmenegger and colleagues presented their study assessing real-world utilization of the alpha emitter Radium-223 at the prostate cancer poster session at the 2017 CUA annual meeting. Based on the ALSYMPCA trial, we know that Radium-223 improves survival and delays skeletal related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) to the bone.¹

Published June 26, 2017
EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D. Heinrich,¹ C. Parker,² M. Shan,³ S. Wilhelm,³ M. Wahba,³ J. Garcia-Vargas,³ C.G. O’Bryan-Tear,⁴ O. Sartor⁵ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Published April 16, 2014
TAT-10: Changes to Alkaline Phosphatase Dynamics and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 in an International Early Access Program
Kanazawa, Japan (UroToday.com) Identifying a reliable marker that is highly correlated with improved overall survival and reduced adverse events for Ra223 treatment would greatly aid the clinical management of metastatic castration-resistant prostate cancer (mCRPC) patients. Bone alkaline phosphate (ALP) is a marker for osteoblasts in bone tissue.

Published June 21, 2017
TAT-10: Radium 223 from Bench to Bedside, and Future Directions for Targeted Alpha Therapy
Kanazawa, Japan (UroToday.com) Dr. Joe O’Sullivan, a Professor of Radiation Oncology at Queen’s College, briefly reviewed the history of radiation treatment of cancer (and prostate cancer in particular) beginning with Radium treatment only eight years after its discovery by the Curies. A landmark paper on radioactive phosphorous treatment of bone-metastatic prostate cancer was published in the journal Lancet in 1964. More recent internal treatments have concentrated on calcium analogs that are directly absorbed in the bone tumor, starting with Sr98, a beta emitter. Single agent beta emitters showed some (~50 %) palliative response but no benefit for overall survival.

Published June 21, 2017

ALSYMPCA Trial Articles

Articles

24th Int'l Prostate Cancer Update: Poster - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

A Review on the Development of Targeted Alpha Therapy in the Treatment of Cancer

ASCO 2013 - Poster: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes

CUA 2017: Analysis of Real-World use of Radium-223 in Ontario

EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial

TAT-10: Changes to Alkaline Phosphatase Dynamics and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 in an International Early Access Program

TAT-10: Radium 223 from Bench to Bedside, and Future Directions for Targeted Alpha Therapy

Login